Related references
Note: Only part of the references are listed.Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer
Rafael Caparica et al.
CLINICAL BREAST CANCER (2020)
What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer?
Mariana Brandao et al.
CLINICAL CANCER RESEARCH (2020)
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors
Maria Vittoria Dieci et al.
CANCER TREATMENT REVIEWS (2020)
Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831
Katherine L. Pogue-Geile et al.
JNCI CANCER SPECTRUM (2020)
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer
Rim S. Kim et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
Gaia Griguolo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F. Cardoso et al.
ANNALS OF ONCOLOGY (2019)
Escalation and de-escalation in HER2 positive early breast cancer
Maria Vittoria Dieci et al.
CURRENT OPINION IN ONCOLOGY (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Anti-tumor effects of propranolol: Adjuvant activity on a transplanted murine breast cancer model
Somayeh Ashrafi et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert et al.
LANCET ONCOLOGY (2018)
Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit
Tiziana Triulzi et al.
BRITISH JOURNAL OF CANCER (2018)
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
Miguel Martin et al.
LANCET ONCOLOGY (2017)
Effects of aerobic exercise training on ACE and ADRB2 gene expression, plasma angiotensin II level, and flow-mediated dilation: a study on obese postmenopausal women with prehypertension
Noushin Azadpour et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2017)
HER2-positive breast cancer is lost in translation: time for patient-centered research
Isabelle Gingras et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
Gunter von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to Preoperative Trastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer
Vinay Varadan et al.
CLINICAL CANCER RESEARCH (2016)
Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer
Edith A. Perez et al.
JAMA ONCOLOGY (2016)
Physical activity, risk of death and recurrence in breast cancer survivors: A systematic review and meta-analysis of epidemiological studies
Ian Matthew Lahart et al.
ACTA ONCOLOGICA (2015)
A Her2-let-7-β2-AR circuit affects prognosis in patients with Her2-positive breast cancer
Dan Liu et al.
BMC CANCER (2015)
Norepinephrine preferentially modulates memory CD8 T cell function inducing inflammatory cytokine production and reducing proliferation in response to activation
Christina Slota et al.
BRAIN BEHAVIOR AND IMMUNITY (2015)
Intrinsic Subtypes, PIK3CA Mutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 Trial
Katherine L. Pogue-Geile et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
Sylvia Adams et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31
Katherine L. Pogue-Geile et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Src activation by β-adrenoreceptors is a key switch for tumour metastasis
Guillermo N. Armaiz-Pena et al.
NATURE COMMUNICATIONS (2013)
A Three-Gene Model to Robustly Identify Breast Cancer Molecular Subtypes
Benjamin Haibe-Kains et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Insights into the regulation of protein abundance from proteomic and transcriptomic analyses
Christine Vogel et al.
NATURE REVIEWS GENETICS (2012)
The beta 2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells
Ming Shi et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The structural basis for agonist and partial agonist action on a β1-adrenergic receptor
Tony Warne et al.
NATURE (2011)
Stress and breast cancer: from epidemiology to molecular biology
Lilia Antonova et al.
BREAST CANCER RESEARCH (2011)
The Sympathetic Nervous System Induces a Metastatic Switch in Primary Breast Cancer
Erica K. Sloan et al.
CANCER RESEARCH (2010)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Correlation of mRNA and protein in complex biological samples
Tobias Maier et al.
FEBS LETTERS (2009)
Trastuzumab in the adjuvant treatment of early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials
Issa J. Dahabreh et al.
ONCOLOGIST (2008)
An economic evaluation of Herceptin® in adjuvant setting:: The Breast Cancer International Research Group 006 trial
M Neyt et al.
ANNALS OF ONCOLOGY (2006)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A versatile assay for high-throughput gene expression profiling on universal array matrices
JB Fan et al.
GENOME RESEARCH (2004)
Share Paper
